The Business Of CNS with Acumen's Jim Doherty, Ph.D.

Business Of Biotech

Вміст надано Matt Pillar. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією Matt Pillar або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.

1M ago 47:51

MP3•Головна епізоду

We love to hear from our listeners. Send us a message.

Life Science Leader's Ben Comer and Acumen Pharmaceuticals' Dr. Jim Doherty join the Business of Biotech to discuss Dr. Doherty's lifelong, singular focus on researching therapeis for CNS diseases. We cover the historical challenges associated with the development of new therapeutics for Alzheimer’s disease, advances in the space, the controversies that have ensued on the heels of recent amlyloid-targeting drug approvals, and where Acumen Pharmaceuticals and its lead candidate, Sabirnetug, fit on the landscape. We also cover the critical and growing role of biomarkers in matching Alzheimer's therapies to specific patients, and assess the growing demand for CNS therapeutics.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Розділи

1. The Business Of CNS with Acumen's Jim Doherty, Ph.D. (00:00:00)

2. Neuroscience and Alzheimer's Therapeutics (00:00:04)

3. Advancements in Alzheimer's Therapeutics (00:14:09)

4. Subcutaneous Formulation for Alzheimer's Therapy (00:28:03)

5. Creating a Strategic Path for Success (00:37:11)

244 епізодів

#Science #MBA #Biology #Business #Matt Pillar #Biopharmaceutical #Bioprocess #Biopharma #Medicine #Therapy #Startup #Venturecapital #Entrepreneur #Pharma #Biotech